Journal article

Fine-tuning chemotherapy in the era of dual HER2 targeting

Sherene Loi

The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2018


Funding Acknowledgements

I have received grants from Novartis, Bristol Meyers Squibb, Roche-Genentech, Puma Biotechnology, and Pfizer, and served on advisory boards (uncompensated) for Seattle Genetics, Pfizer Novartis, Bristol Myers-Squibb, Merck, and Roche-Genentech, outside the submitted work. I am supported by the National Breast Cancer Foundation (NBCF) of Australia.